Metastatic Cancer, HER2 Gene Mutation
Conditions
Brief summary
Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar)
Detailed description
1. Primary objective Evaluate overall response rate (ORR) in HER2 mutated advanced solid cancer patients based on RECIST v1.1 2. Secondary objectives (1) Evaluate clinical benefit rate (CBR) (2) Evaluate duration of response (DOR) (3) Evaluate progression free survival (PFS) (4) Evaluate overall survival (OS) (5) Evaluate compliance with oral administration 3) Safety evaluation 1. Evaluate the overall safety of the test drug 2. Evaluate the predefined adverse event (diarrhea)
Interventions
* neratinib 240mg po daily * herzuma 8mg/kg (loading) --\> 6mg/kg q3w
Sponsors
Korean Cancer Study Group
Korea University Guro Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who voluntarily decide to participate and give written consent after hearing the explanation of the clinical trial and investigational drugs. * Adult men and women over 19 years old. * Histological or cytological confirmed advanced solid tumor and confirmed to have HER2 known oncogenic mutations in tumor DNA by K-master panel test using tumor tissues or circulating tumor DNA in blood. * Patients having at least 1 or more than 1 measurable lesion according to RECIST v 1.1. * Eastern Cooperative Oncology Group (ECOG) performance status 0\ 2. * Patients whose life expectancy is more than 6 months. * Metastatic/progressive solid cancer patients who have received one or more than one standard treatment or do not have any treatment option. * Patients who have agreed to provide plasma/blood samples, the most recent metastatic/progressive tumor sample or new tumor biopsy for gene sequencing and other biomarker analysis.
Exclusion criteria
* Patients who received radiotherapy or surgical treatment within 2 weeks prior to the initiation of investigational product. * Patients having symptomatic brain metastasis who needs treatment. Patients with stable brain metastasis who need no treatment including steroid are eligible * Inappropriate HER2 mutation (e.g., non-Hot Spot mutation, variant of unknown siginificance, subclonal mutation, premature STOP codon or the Frame Shift mutation). * Patients having difficulties in swallowing tablets. * Patients with toxicities of prior treatment which are not recovered to baseline level or ≤ Grade 1. * Inadequate organ functions: 1. Hemoglobin (Hemoglobin) \< 8 .0g / dL 2. Absolute neutrophil count (ANC) \< 1. 0 x10 ³ per mm³ 3. Platelet count \< 100 x10⁹/L (100 ,000/ mm³) 4. Total bilirubin \> 1.5 x upper normal limits (UNL), (exclude Gilbert's syndrome) 5. Alanine aminotransferase (ALT) or aspartate amino transferase (AST) \> 3 x upper normal limits (UNL) (in case of liver and bone metastases \> 5 x ULN) 6. Serum creatinine \>1.5 x upper normal limits (UNL) or \< eGFR 30 mL/min/1.73 m² 7) Left ventricle ejection fraction \<50% by multi-gate obtaining method scan (MUGA) or echocardiogram. 8\) Chronic gastrointestinal disorders of which a main symptom is diarrhea (e.g., Crohn's disease, malabsorption, or grade 2 or more than grade 2 diarrhea according to the NCI CTCAE version 5.0 regardless of etiology).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate (ORR) | at 6 months | ORR according to RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| clinical benefit rate, CBR | at 6 months | CR+PR + SD more than 12 weeks |
| median duration of response, DOR | at 6 months | DOR is related to the quality of life and is one of the methods for evaluating tumor response approved by pharmaceutical regulatory agencies |
| median progression free survival, PFS | at 6 months | from enrollment to disease progression, death or withdrawal |
| safety profiles | at 6 months | safety profiles according to CTCAE 4.0 |
Countries
South Korea
Outcome results
None listed